nodes	percent_of_prediction	percent_of_DWPC	metapath
Lorazepam—Constipation—Pentoxifylline—systemic scleroderma	0.00217	0.00218	CcSEcCtD
Lorazepam—Bradycardia—Mycophenolic acid—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Lorazepam—Chills—Azathioprine—systemic scleroderma	0.00212	0.00213	CcSEcCtD
Lorazepam—Hallucination—Mycophenolic acid—systemic scleroderma	0.00212	0.00212	CcSEcCtD
Lorazepam—Arrhythmia—Azathioprine—systemic scleroderma	0.00211	0.00212	CcSEcCtD
Lorazepam—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.00209	0.0021	CcSEcCtD
Lorazepam—Alopecia—Azathioprine—systemic scleroderma	0.00209	0.00209	CcSEcCtD
Lorazepam—Jaundice—Lisinopril—systemic scleroderma	0.00208	0.00209	CcSEcCtD
Lorazepam—Visual impairment—Mycophenolic acid—systemic scleroderma	0.00205	0.00206	CcSEcCtD
Lorazepam—Pulmonary oedema—Prednisone—systemic scleroderma	0.00202	0.00202	CcSEcCtD
Lorazepam—Dysarthria—Methotrexate—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Lorazepam—Chills—Leflunomide—systemic scleroderma	0.002	0.00201	CcSEcCtD
Lorazepam—Arrhythmia—Leflunomide—systemic scleroderma	0.002	0.002	CcSEcCtD
Lorazepam—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00199	0.002	CcSEcCtD
Lorazepam—Agranulocytosis—Lisinopril—systemic scleroderma	0.00199	0.002	CcSEcCtD
Lorazepam—Alopecia—Leflunomide—systemic scleroderma	0.00197	0.00198	CcSEcCtD
Lorazepam—Dry mouth—Captopril—systemic scleroderma	0.00196	0.00197	CcSEcCtD
Lorazepam—Bradycardia—Lisinopril—systemic scleroderma	0.00195	0.00196	CcSEcCtD
Lorazepam—Euphoric mood—Prednisone—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Lorazepam—Confusional state—Captopril—systemic scleroderma	0.00194	0.00194	CcSEcCtD
Lorazepam—Erectile dysfunction—Mycophenolate mofetil—systemic scleroderma	0.00193	0.00194	CcSEcCtD
Lorazepam—Respiratory failure—Methotrexate—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Lorazepam—Chills—Mycophenolic acid—systemic scleroderma	0.00191	0.00192	CcSEcCtD
Lorazepam—Hallucination—Lisinopril—systemic scleroderma	0.00191	0.00191	CcSEcCtD
Lorazepam—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.0019	0.00191	CcSEcCtD
Lorazepam—Fatigue—Mometasone—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Lorazepam—Thrombocytopenia—Captopril—systemic scleroderma	0.00188	0.00189	CcSEcCtD
Lorazepam—Alopecia—Mycophenolic acid—systemic scleroderma	0.00188	0.00189	CcSEcCtD
Lorazepam—Tachycardia—Captopril—systemic scleroderma	0.00188	0.00188	CcSEcCtD
Lorazepam—Pain—Mometasone—systemic scleroderma	0.00187	0.00188	CcSEcCtD
Lorazepam—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00187	0.00187	CcSEcCtD
Lorazepam—Cystitis noninfective—Methotrexate—systemic scleroderma	0.00185	0.00186	CcSEcCtD
Lorazepam—Vision blurred—Leflunomide—systemic scleroderma	0.00183	0.00184	CcSEcCtD
Lorazepam—Cystitis—Methotrexate—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Lorazepam—Depressed level of consciousness—Methotrexate—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Lorazepam—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Lorazepam—Asthenia—Pentoxifylline—systemic scleroderma	0.00182	0.00183	CcSEcCtD
Lorazepam—Tension—Mycophenolic acid—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Lorazepam—Nervousness—Mycophenolic acid—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Lorazepam—Hypotension—Captopril—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Lorazepam—Amnesia—Prednisone—systemic scleroderma	0.00175	0.00176	CcSEcCtD
Lorazepam—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Lorazepam—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Lorazepam—Vertigo—Leflunomide—systemic scleroderma	0.00175	0.00175	CcSEcCtD
Lorazepam—Tremor—Mycophenolic acid—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Lorazepam—Coma—Methotrexate—systemic scleroderma	0.00173	0.00174	CcSEcCtD
Lorazepam—Chills—Lisinopril—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Lorazepam—Bladder pain—Methotrexate—systemic scleroderma	0.00171	0.00172	CcSEcCtD
Lorazepam—Arrhythmia—Lisinopril—systemic scleroderma	0.00171	0.00172	CcSEcCtD
Lorazepam—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Lorazepam—Somnolence—Captopril—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Lorazepam—Agitation—Mycophenolic acid—systemic scleroderma	0.0017	0.00171	CcSEcCtD
Lorazepam—Alopecia—Lisinopril—systemic scleroderma	0.0017	0.0017	CcSEcCtD
Lorazepam—Pulmonary oedema—Methotrexate—systemic scleroderma	0.00169	0.00169	CcSEcCtD
Lorazepam—Lethargy—Prednisone—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Lorazepam—Dizziness—Pentoxifylline—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Lorazepam—Hypertension—Leflunomide—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Lorazepam—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00167	0.00168	CcSEcCtD
Lorazepam—Erythema—Lisinopril—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Lorazepam—Infection—Azathioprine—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Lorazepam—Vertigo—Mycophenolic acid—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Lorazepam—Fatigue—Captopril—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Lorazepam—Gastrointestinal haemorrhage—Prednisone—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Lorazepam—Osteoarthritis—Prednisone—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Lorazepam—Constipation—Captopril—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Lorazepam—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Lorazepam—Tension—Lisinopril—systemic scleroderma	0.00164	0.00164	CcSEcCtD
Lorazepam—Nervousness—Lisinopril—systemic scleroderma	0.00162	0.00163	CcSEcCtD
Lorazepam—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Lorazepam—Dry mouth—Leflunomide—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Lorazepam—Vomiting—Pentoxifylline—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Lorazepam—Psychotic disorder—Prednisone—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Lorazepam—Convulsion—Mycophenolic acid—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Lorazepam—Rash—Pentoxifylline—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Lorazepam—Hypertension—Mycophenolic acid—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Lorazepam—Dermatitis—Pentoxifylline—systemic scleroderma	0.0016	0.0016	CcSEcCtD
Lorazepam—Headache—Pentoxifylline—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Lorazepam—Feeling abnormal—Captopril—systemic scleroderma	0.00159	0.00159	CcSEcCtD
Lorazepam—Infection—Leflunomide—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Lorazepam—Vision blurred—Lisinopril—systemic scleroderma	0.00157	0.00158	CcSEcCtD
Lorazepam—Asthenia—Mometasone—systemic scleroderma	0.00157	0.00158	CcSEcCtD
Lorazepam—Irritability—Prednisone—systemic scleroderma	0.00157	0.00158	CcSEcCtD
Lorazepam—Hypotension—Azathioprine—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Lorazepam—Cardiac arrest—Prednisone—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Lorazepam—Tremor—Lisinopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Lorazepam—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00155	0.00156	CcSEcCtD
Lorazepam—Tachycardia—Leflunomide—systemic scleroderma	0.00155	0.00155	CcSEcCtD
Lorazepam—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00154	0.00155	CcSEcCtD
Lorazepam—Confusional state—Mycophenolic acid—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Lorazepam—Nausea—Pentoxifylline—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Lorazepam—Chills—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Lorazepam—Infection—Mycophenolic acid—systemic scleroderma	0.0015	0.00151	CcSEcCtD
Lorazepam—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Lorazepam—Vertigo—Lisinopril—systemic scleroderma	0.0015	0.0015	CcSEcCtD
Lorazepam—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.00149	0.00149	CcSEcCtD
Lorazepam—Hypotension—Leflunomide—systemic scleroderma	0.00148	0.00149	CcSEcCtD
Lorazepam—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Lorazepam—Tachycardia—Mycophenolic acid—systemic scleroderma	0.00148	0.00148	CcSEcCtD
Lorazepam—Visual disturbance—Methotrexate—systemic scleroderma	0.00145	0.00146	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Lorazepam—Tension—Mycophenolate mofetil—systemic scleroderma	0.00144	0.00144	CcSEcCtD
Lorazepam—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Lorazepam—Hypotension—Mycophenolic acid—systemic scleroderma	0.00141	0.00142	CcSEcCtD
Lorazepam—Lethargy—Methotrexate—systemic scleroderma	0.00141	0.00141	CcSEcCtD
Lorazepam—Vomiting—Mometasone—systemic scleroderma	0.00139	0.0014	CcSEcCtD
Lorazepam—Dry mouth—Lisinopril—systemic scleroderma	0.00139	0.00139	CcSEcCtD
Lorazepam—Feeling abnormal—Azathioprine—systemic scleroderma	0.00138	0.00139	CcSEcCtD
Lorazepam—Rash—Mometasone—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Lorazepam—Asthenia—Captopril—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Lorazepam—Dermatitis—Mometasone—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Lorazepam—Osteoarthritis—Methotrexate—systemic scleroderma	0.00138	0.00138	CcSEcCtD
Lorazepam—Confusional state—Lisinopril—systemic scleroderma	0.00137	0.00138	CcSEcCtD
Lorazepam—Headache—Mometasone—systemic scleroderma	0.00137	0.00138	CcSEcCtD
Lorazepam—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Lorazepam—Fatigue—Leflunomide—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Lorazepam—Pain—Leflunomide—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Lorazepam—Constipation—Leflunomide—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Lorazepam—Infection—Lisinopril—systemic scleroderma	0.00135	0.00136	CcSEcCtD
Lorazepam—Somnolence—Mycophenolic acid—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Lorazepam—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Lorazepam—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00133	0.00134	CcSEcCtD
Lorazepam—Tachycardia—Lisinopril—systemic scleroderma	0.00133	0.00133	CcSEcCtD
Lorazepam—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00131	0.00132	CcSEcCtD
Lorazepam—Irritability—Methotrexate—systemic scleroderma	0.00131	0.00132	CcSEcCtD
Lorazepam—Erectile dysfunction—Prednisone—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Lorazepam—Feeling abnormal—Leflunomide—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00131	0.00131	CcSEcCtD
Lorazepam—Fatigue—Mycophenolic acid—systemic scleroderma	0.0013	0.00131	CcSEcCtD
Lorazepam—Nausea—Mometasone—systemic scleroderma	0.0013	0.0013	CcSEcCtD
Lorazepam—Ataxia—Methotrexate—systemic scleroderma	0.00129	0.0013	CcSEcCtD
Lorazepam—Pain—Mycophenolic acid—systemic scleroderma	0.00129	0.0013	CcSEcCtD
Lorazepam—Constipation—Mycophenolic acid—systemic scleroderma	0.00129	0.0013	CcSEcCtD
Lorazepam—Hypotension—Lisinopril—systemic scleroderma	0.00127	0.00128	CcSEcCtD
Lorazepam—Dizziness—Captopril—systemic scleroderma	0.00127	0.00128	CcSEcCtD
Lorazepam—Liver function test abnormal—Methotrexate—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Lorazepam—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Lorazepam—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00126	0.00127	CcSEcCtD
Lorazepam—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00125	0.00125	CcSEcCtD
Lorazepam—Hypersensitivity—Azathioprine—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Lorazepam—Vomiting—Captopril—systemic scleroderma	0.00122	0.00123	CcSEcCtD
Lorazepam—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Lorazepam—Rash—Captopril—systemic scleroderma	0.00121	0.00122	CcSEcCtD
Lorazepam—Dermatitis—Captopril—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Lorazepam—Somnolence—Lisinopril—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Lorazepam—Headache—Captopril—systemic scleroderma	0.00121	0.00121	CcSEcCtD
Lorazepam—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.0012	0.00121	CcSEcCtD
Lorazepam—Infection—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00119	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Lorazepam—Fatigue—Lisinopril—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Lorazepam—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Lorazepam—Hypersensitivity—Leflunomide—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Lorazepam—Constipation—Lisinopril—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Lorazepam—Pain—Lisinopril—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Lorazepam—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Lorazepam—Bradycardia—Prednisone—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Lorazepam—Nausea—Captopril—systemic scleroderma	0.00114	0.00115	CcSEcCtD
Lorazepam—Asthenia—Leflunomide—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Lorazepam—Hallucination—Prednisone—systemic scleroderma	0.00113	0.00114	CcSEcCtD
Lorazepam—Pancytopenia—Methotrexate—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Lorazepam—Feeling abnormal—Lisinopril—systemic scleroderma	0.00112	0.00113	CcSEcCtD
Lorazepam—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Lorazepam—Dizziness—Azathioprine—systemic scleroderma	0.00111	0.00111	CcSEcCtD
Lorazepam—Erectile dysfunction—Methotrexate—systemic scleroderma	0.0011	0.0011	CcSEcCtD
Lorazepam—Asthenia—Mycophenolic acid—systemic scleroderma	0.00109	0.00109	CcSEcCtD
Lorazepam—Vomiting—Azathioprine—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Lorazepam—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Lorazepam—Drowsiness—Methotrexate—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Lorazepam—Rash—Azathioprine—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Lorazepam—Dermatitis—Azathioprine—systemic scleroderma	0.00106	0.00106	CcSEcCtD
Lorazepam—Headache—Azathioprine—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Lorazepam—Dizziness—Leflunomide—systemic scleroderma	0.00105	0.00105	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Lorazepam—Pain—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Lorazepam—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Lorazepam—Arrhythmia—Prednisone—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Lorazepam—Vomiting—Leflunomide—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Lorazepam—Alopecia—Prednisone—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Lorazepam—Hypersensitivity—Lisinopril—systemic scleroderma	0.001	0.00101	CcSEcCtD
Lorazepam—Dizziness—Mycophenolic acid—systemic scleroderma	0.001	0.001	CcSEcCtD
Lorazepam—Rash—Leflunomide—systemic scleroderma	0.001	0.001	CcSEcCtD
Lorazepam—Dermatitis—Leflunomide—systemic scleroderma	0.000999	0.001	CcSEcCtD
Lorazepam—Nausea—Azathioprine—systemic scleroderma	0.000998	0.001	CcSEcCtD
Lorazepam—Headache—Leflunomide—systemic scleroderma	0.000994	0.000996	CcSEcCtD
Lorazepam—Erythema—Prednisone—systemic scleroderma	0.000992	0.000994	CcSEcCtD
Lorazepam—Agranulocytosis—Methotrexate—systemic scleroderma	0.00099	0.000992	CcSEcCtD
Lorazepam—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000984	0.000986	CcSEcCtD
Lorazepam—Asthenia—Lisinopril—systemic scleroderma	0.000978	0.00098	CcSEcCtD
Lorazepam—Vomiting—Mycophenolic acid—systemic scleroderma	0.000962	0.000964	CcSEcCtD
Lorazepam—Rash—Mycophenolic acid—systemic scleroderma	0.000954	0.000956	CcSEcCtD
Lorazepam—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000953	0.000955	CcSEcCtD
Lorazepam—Headache—Mycophenolic acid—systemic scleroderma	0.000948	0.00095	CcSEcCtD
Lorazepam—Nausea—Leflunomide—systemic scleroderma	0.000942	0.000944	CcSEcCtD
Lorazepam—Vision blurred—Prednisone—systemic scleroderma	0.000935	0.000937	CcSEcCtD
Lorazepam—Visual impairment—Methotrexate—systemic scleroderma	0.000918	0.00092	CcSEcCtD
Lorazepam—Agitation—Prednisone—systemic scleroderma	0.000912	0.000913	CcSEcCtD
Lorazepam—Dizziness—Lisinopril—systemic scleroderma	0.000902	0.000903	CcSEcCtD
Lorazepam—Nausea—Mycophenolic acid—systemic scleroderma	0.000899	0.000901	CcSEcCtD
Lorazepam—Vertigo—Prednisone—systemic scleroderma	0.000891	0.000893	CcSEcCtD
Lorazepam—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00088	0.000882	CcSEcCtD
Lorazepam—Vomiting—Lisinopril—systemic scleroderma	0.000867	0.000868	CcSEcCtD
Lorazepam—Rash—Lisinopril—systemic scleroderma	0.00086	0.000861	CcSEcCtD
Lorazepam—Convulsion—Prednisone—systemic scleroderma	0.00086	0.000861	CcSEcCtD
Lorazepam—Dermatitis—Lisinopril—systemic scleroderma	0.000859	0.00086	CcSEcCtD
Lorazepam—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000857	0.000859	CcSEcCtD
Lorazepam—Hypertension—Prednisone—systemic scleroderma	0.000857	0.000858	CcSEcCtD
Lorazepam—Chills—Methotrexate—systemic scleroderma	0.000855	0.000856	CcSEcCtD
Lorazepam—Headache—Lisinopril—systemic scleroderma	0.000854	0.000856	CcSEcCtD
Lorazepam—Alopecia—Methotrexate—systemic scleroderma	0.000842	0.000843	CcSEcCtD
Lorazepam—Erythema—Methotrexate—systemic scleroderma	0.000829	0.000831	CcSEcCtD
Lorazepam—Nausea—Lisinopril—systemic scleroderma	0.00081	0.000811	CcSEcCtD
Lorazepam—Infection—Prednisone—systemic scleroderma	0.000804	0.000806	CcSEcCtD
Lorazepam—Tachycardia—Prednisone—systemic scleroderma	0.00079	0.000792	CcSEcCtD
Lorazepam—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00079	0.000791	CcSEcCtD
Lorazepam—Vision blurred—Methotrexate—systemic scleroderma	0.000781	0.000783	CcSEcCtD
Lorazepam—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000759	0.000761	CcSEcCtD
Lorazepam—Rash—Mycophenolate mofetil—systemic scleroderma	0.000753	0.000755	CcSEcCtD
Lorazepam—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000752	0.000754	CcSEcCtD
Lorazepam—Headache—Mycophenolate mofetil—systemic scleroderma	0.000748	0.00075	CcSEcCtD
Lorazepam—Vertigo—Methotrexate—systemic scleroderma	0.000745	0.000746	CcSEcCtD
Lorazepam—Convulsion—Methotrexate—systemic scleroderma	0.000718	0.00072	CcSEcCtD
Lorazepam—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00071	0.000711	CcSEcCtD
Lorazepam—Fatigue—Prednisone—systemic scleroderma	0.000698	0.000699	CcSEcCtD
Lorazepam—Constipation—Prednisone—systemic scleroderma	0.000692	0.000694	CcSEcCtD
Lorazepam—Confusional state—Methotrexate—systemic scleroderma	0.000682	0.000684	CcSEcCtD
Lorazepam—Infection—Methotrexate—systemic scleroderma	0.000672	0.000673	CcSEcCtD
Lorazepam—Feeling abnormal—Prednisone—systemic scleroderma	0.000667	0.000668	CcSEcCtD
Lorazepam—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000663	0.000664	CcSEcCtD
Lorazepam—Hypotension—Methotrexate—systemic scleroderma	0.000632	0.000633	CcSEcCtD
Lorazepam—Somnolence—Methotrexate—systemic scleroderma	0.000602	0.000603	CcSEcCtD
Lorazepam—Hypersensitivity—Prednisone—systemic scleroderma	0.000597	0.000598	CcSEcCtD
Lorazepam—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000584	0.000585	CcSEcCtD
Lorazepam—Fatigue—Methotrexate—systemic scleroderma	0.000583	0.000584	CcSEcCtD
Lorazepam—Asthenia—Prednisone—systemic scleroderma	0.000581	0.000582	CcSEcCtD
Lorazepam—Pain—Methotrexate—systemic scleroderma	0.000579	0.00058	CcSEcCtD
Lorazepam—Feeling abnormal—Methotrexate—systemic scleroderma	0.000558	0.000559	CcSEcCtD
Lorazepam—Dizziness—Prednisone—systemic scleroderma	0.000535	0.000536	CcSEcCtD
Lorazepam—Vomiting—Prednisone—systemic scleroderma	0.000515	0.000516	CcSEcCtD
Lorazepam—Rash—Prednisone—systemic scleroderma	0.000511	0.000511	CcSEcCtD
Lorazepam—Dermatitis—Prednisone—systemic scleroderma	0.00051	0.000511	CcSEcCtD
Lorazepam—Headache—Prednisone—systemic scleroderma	0.000507	0.000508	CcSEcCtD
Lorazepam—Hypersensitivity—Methotrexate—systemic scleroderma	0.000499	0.000499	CcSEcCtD
Lorazepam—Asthenia—Methotrexate—systemic scleroderma	0.000486	0.000486	CcSEcCtD
Lorazepam—Nausea—Prednisone—systemic scleroderma	0.000481	0.000482	CcSEcCtD
Lorazepam—Dizziness—Methotrexate—systemic scleroderma	0.000447	0.000448	CcSEcCtD
Lorazepam—Vomiting—Methotrexate—systemic scleroderma	0.00043	0.000431	CcSEcCtD
Lorazepam—Rash—Methotrexate—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Lorazepam—Dermatitis—Methotrexate—systemic scleroderma	0.000426	0.000427	CcSEcCtD
Lorazepam—Headache—Methotrexate—systemic scleroderma	0.000424	0.000425	CcSEcCtD
Lorazepam—Nausea—Methotrexate—systemic scleroderma	0.000402	0.000403	CcSEcCtD
Lorazepam—TSPO—artery—systemic scleroderma	0.00035	0.196	CbGeAlD
Lorazepam—UGT2B15—digestive system—systemic scleroderma	0.000282	0.158	CbGeAlD
Lorazepam—TSPO—blood vessel—systemic scleroderma	0.000273	0.153	CbGeAlD
Lorazepam—TSPO—connective tissue—systemic scleroderma	0.00014	0.0784	CbGeAlD
Lorazepam—TSPO—smooth muscle tissue—systemic scleroderma	0.000128	0.0717	CbGeAlD
Lorazepam—GABRB3—connective tissue—systemic scleroderma	0.000127	0.0712	CbGeAlD
Lorazepam—TSPO—skin of body—systemic scleroderma	0.000126	0.0708	CbGeAlD
Lorazepam—TSPO—digestive system—systemic scleroderma	0.000101	0.0566	CbGeAlD
Lorazepam—TSPO—tendon—systemic scleroderma	9.61e-05	0.0539	CbGeAlD
Lorazepam—TSPO—lung—systemic scleroderma	8.43e-05	0.0473	CbGeAlD
Lorazepam—GABRB3—lung—systemic scleroderma	7.65e-05	0.0429	CbGeAlD
